MK-7 Segment by Product to Account Largest Share in Vitamin K2 Market during 2022–2030.    

According to our new research study on "Vitamin K2 Market Forecast to 2030 –Global Analysis – by product, dosage forms, source, and application," the market was valued at US$ 1,44,571.42 Thousands in 2022; and is expected to reach US$ 11,60,779.02 Thousands by 2030 and it estimated to grow at a rate of 29.7% from 2022 to 2030. The report highlights trends prevailing in the market, and factors driving and hindering the vitamin K2 market growth.

The vitamin K2 market growth is due to the increasing prevalence of CVD and growing cases of osteoporosis in adults and newborns. Whereas limited awareness regarding benefits of vitamin K2 is hindering the market growth.

The vitamin K2 market, by product, is segmented into MK-4, MK-7, and combination drugs. In 2022, the MK-7 segment held the largest market share, and it is estimated to register the fastest CAGR during 2022–2030.  Menaquinone-7 (MK-7) is an advanced, fat-soluble form of vitamin K2 that serves multiple bodily functions. Only vitamin K2 in the form of MK-7 has been proven to provide 24-hour protection to bones and teeth from a single daily dose. MK-7 has a much longer half-life in the body and stays in the blood the longest than other forms of vitamin K2, owing to its presence not only in liver tissues but also in bones, arteries, and soft tissues. Therefore, MK-7 supplementation must only be taken once daily. According to MenaQ7, 45 mcg of MK-7 per day can increase carboxylation and activate vitamin K-dependent proteins, such as osteocalcin for bone health and Matrix GLA Protein (MGP) for heart health.

In terms of geography, the global vitamin K2 market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America.

The market in North America is further divided into the US, Canada, and Mexico. North America holds the largest share of the vitamin K2 market. The market growth in North America is attributed to the rising adoption of nutraceutical supplements for vitamin K2. In addition, the increasing prevalence of cardiovascular diseases and orthopedic disorders, along with rising cases of vitamin K2 deficiency in children and geriatric population, is expected to fuel the vitamin K2 market.

The US accounts for the largest share of the vitamin K2 market in North America. The increasing prevalence of cardiovascular diseases and orthopedic disorders, such as osteoporosis and arthritis, has increased the demand for vitamin K2, as it helps in the better absorption of calcium and other nutrients, strengthening cardiac and bone health. According to the Centers for Disease Control and Prevention (CDC), in 2021, ~695,000 people died from heart disease in the US, coronary heart disease being the most common type of heart disease that resulted in the death of 375,476 people in the country. Moreover, various strategic developments such as product launches, acquisitions, and mergers have been taking place in the country, which are contributing to the market growth. In October 2022, Kappa Bioscience launched its first organic grade vitamin K2-MK7 in the US market under the brand name K2Vital. It is the first US Department of Agriculture (USDA) organic-certified all-trans, all-bioactive vitamin K2-MK7 for oil-based health applications in the US market. Therefore, the rising prevalence of cardiovascular diseases and orthopedic disorders, along with an increase in strategic collaboration, is expected to drive the vitamin K2 market growth in the US.

Lesaffre, DSM-Firmenich, BIOLAB FARMACÊUTICA, PLT Health Solutions, BASF SE, AdvaCare Pharma, Metabolics ltd, Yamamoto Nutrition, and Fermenta Biotech Limited are among the leading companies operating in the vital signs monitoring devices market.    

Companies operating in the vitamin K2 market adopt various organic and inorganic strategies. Growth strategies mainly include product launches and product approvals, mergers & acquisitions, collaborations, and partnerships are among the growth strategies witnessed in the vitamin K2 market.

A few of the significant developments by key market players are listed below.

Various initiatives taken by leading players operating in the vitamin K2 market are listed below:

• In June 2022, Balchem Corporation announced the complete acquisition of Kappa Bioscience AS. The acquisition has helped Balchem expand its product portfolio by adding Kappa Bioscience AS's specialty vitamin K2.
• In October 2022, PLT Health Solutions, Inc. announced that non-GMO Project company offered it non-GMO verification for its menatto. In March 2022, the company introduced menatto in the US, which is manufactured by edible oils producer J-Oil Mills, Tokyo, Japan.
• In May 2023, DSM merged into Firmenich to create a robust platform for reinventing, manufacturing, and combining vital nutrients, flavors, and fragrances. The announcement was made to create a new brand called dsm-firmenich, under which the companies will have a competitive edge and growth opportunities for nutrition, health, and beauty segments.
• In April 2023, DSM announced negotiations with Adare Pharma Solutions to acquire its Adare Biome for US$ 301.2 million (€275 million). The acquisition will enable DSM to expand its human health and animal nutrition offerings.     

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com